Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 17, Issue -, Pages 2327-2349Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/4055
Keywords
Endothelial progenitor cells; Atherosclerosis; Inflammation; Review
Categories
Funding
- National Institutes of Health [HL094451, HL108910, HL67033, HL82774, HL77288]
Ask authors/readers for more resources
Endothelial progenitor cells (EPCs) are involved in the maintenance of endothelial homoeostasis and in the process of new vessel formation. Experimental and clinical studies have shown that atherosclerosis is associated with reduced numbers and dysfunction of EPCs; and that medications alone are able to partially reverse the impairment of EPCs in patients with atherosclerosis. Therefore, novel EPC-based therapies may provide enhancement in restoring EPCs' population and improvement of vascular function. Here, for a better understanding of the molecular mechanisms underlying EPC impairment in atherosclerosis, we provide a comprehensive overview on EPC characteristics, phenotypes, and the signaling pathways underlying EPC impairment in atherosclerosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available